Literature DB >> 21274674

Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors.

Hamdy E Abouzeid1, Abdel Meguid Kassem, Abdel Hady Abdel Wahab, Hatem A El-mezayen, Hayaat Sharad, Shaimaa Abdel Rahman.   

Abstract

Hypermethylation at the promoter region is an important epigenetic mechanism underlying the inactivation of tumor suppressor genes and frequently occurs as an early event in the development of different types of cancer including colorectal carcinoma (CRC). The aim of the present study is the detection of methylation status for some tumor suppressor genes including RASSF1A, MGMT, and HIC-1 in both cancerous and precancerous lesions of colorectal mucosa to evaluate the possibility of developing epigenetic biomarker for early detection of Egyptian CRC. Tissue biopsy was collected from 72 patients (36 CRC, 17 adenomatous polyps, and 19 ulcerative colitis), and in addition, adjacent normal-appearing tissues were collected as control. Promoter hypermethylation status for RSSAF1A, MGMT, and HIC-1 genes was detected after isolation of genomic DNA from the tissues samples using methylation-specific PCR technique. High frequency of methylation at MGMT, RASSFA, and HIC-1 was detected in CRC patients (25%, 47.2%, and 41.7% respectively). The highest methylation detected in adenomatous polyps patients was in MGMT gene (47.1%) followed by 35.3% for HIC-1 and only 5.9% for RASSF1A gene. HIC-1 gene exhibited highest frequency of methylation in ulcerative colitis patients (57.8%) whereas it was 26.3% for both RASSF1A and MGMT genes. A nonsignificant association was recorded between the methylation status in different genes examined with the clinicopathological factors except the association between methylation at RASSF1A gene with gender (p=0.005), and it was significant. In conclusion, aberrant hypermethylation at promoter region of RASSFA, MGMT, and HIC-1 genes is involved in Egyptian CRCs. Hypermethylation of MGMT and HIC-1 genes plays an important role in the initiation of disease especially ulcerative colitis-carcinoma pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274674     DOI: 10.1007/s13277-011-0156-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 2.  The tumor suppressor RASSF1A in human carcinogenesis: an update.

Authors:  R Dammann; U Schagdarsurengin; C Seidel; M Strunnikova; M Rastetter; K Baier; G P Pfeifer
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

3.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer.

Authors:  Manon van Engeland; Guido M J M Roemen; Mirian Brink; Marco M M Pachen; Matty P Weijenberg; Adriaan P de Bruïne; Jan-Willem Arends; Piet A van den Brandt; Anton F P M de Goeij; James G Herman
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

4.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

Authors:  Manel Esteller; Gianluca Gaidano; Steven N Goodman; Vittorina Zagonel; Daniela Capello; Barbara Botto; Davide Rossi; Annunziata Gloghini; Umberto Vitolo; Antonino Carbone; Stephen B Baylin; James G Herman
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

Review 6.  Epigenetic changes in colorectal cancer.

Authors:  Yutaka Kondo; Jean-Pierre J Issa
Journal:  Cancer Metastasis Rev       Date:  2004 Jan-Jun       Impact factor: 9.264

7.  Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.

Authors:  Yu-Cai Wang; Zheng-Hong Yu; Chang Liu; Li-Zhi Xu; Wen Yu; Jia Lu; Ren-Min Zhu; Guo-Li Li; Xin-Yi Xia; Xiao-Wei Wei; Hong-Zan Ji; Heng Lu; Yong Gao; Wei-Min Gao; Long-Bang Chen
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

8.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Authors:  M M Wales; M A Biel; W el Deiry; B D Nelkin; J P Issa; W K Cavenee; S J Kuerbitz; S B Baylin
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

9.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.

Authors:  Takeshi Nagasaka; Ajay Goel; Kenji Notohara; Takaomi Takahata; Hiromi Sasamoto; Takuyuki Uchida; Naoshi Nishida; Noriaki Tanaka; Clement Richard Boland; Nagahide Matsubara
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

View more
  23 in total

1.  Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.

Authors:  He-Ling Wang; Yu Zhang; Peng Liu; Ping-Yi Zhou
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

Review 2.  The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis.

Authors:  Lele Song; Yuemin Li
Journal:  Stem Cell Rev Rep       Date:  2016-10       Impact factor: 5.739

3.  Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism.

Authors:  Fabio Coppedè; Francesca Migheli; Angela Lopomo; Alessandra Failli; Annalisa Legitimo; Rita Consolini; Gabriella Fontanini; Elisa Sensi; Adele Servadio; Massimo Seccia; Giuseppe Zocco; Massimo Chiarugi; Roberto Spisni; Lucia Migliore
Journal:  Epigenetics       Date:  2014-01-31       Impact factor: 4.528

4.  Folate deficiency and aberrant DNA methylation and expression of FHIT gene were associated with cervical pathogenesis.

Authors:  Qiaoling Li; Ling Ding; Nan Jing; Chunliang Liu; Zuokai Yang; Fang Chen; Lifang Hou; Jintao Wang
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

5.  Significant association of PRMT6 hypomethylation with colorectal cancer.

Authors:  Ranran Pan; Hang Yu; Jie Dai; Cong Zhou; Xiuru Ying; Jie Zhong; Jun Zhao; Yihan Zhang; Boyi Wu; Yiyi Mao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  J Clin Lab Anal       Date:  2018-06-21       Impact factor: 2.352

Review 6.  Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review.

Authors:  Yanliang Li; Zhongchuan Lyu; Lixin Zhao; Hong Cheng; Dongyuan Zhu; Yongsheng Gao; Xiuwan Shang; Huaijie Shi
Journal:  Tumour Biol       Date:  2015-01-17

7.  Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.

Authors:  Pinelopi Nterma; Eleni Panopoulou; Eleni Papadaki-Petrou; Martha Assimakopoulou
Journal:  Pathol Oncol Res       Date:  2019-01-02       Impact factor: 3.201

8.  Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Authors:  Dimitrios Matthaios; Ioanna Balgkouranidou; Anastasios Karayiannakis; Helen Bolanaki; Nikolaos Xenidis; Kyriakos Amarantidis; Leonidas Chelis; Konstantinos Romanidis; Aikaterini Chatzaki; Evi Lianidou; Grigorios Trypsianis; Stylianos Kakolyris
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

9.  DNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation.

Authors:  Karyn L Sheaffer; Ellen N Elliott; Klaus H Kaestner
Journal:  Cancer Prev Res (Phila)       Date:  2016-02-16

Review 10.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.